What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
Colorectal cancer, Internal medicine, Cancer, Genetics and Gastroenterology are his primary areas of study.
His studies deal with areas such as Survival rate, Pathology and Endometrial cancer as well as Colorectal cancer.
His study explores the link between Internal medicine and topics such as Oncology that cross with problems in Microsatellite instability.
Within one scientific family, Heikki Järvinen focuses on topics pertaining to Surgery under Cancer, and may sometimes address concerns connected to Relative risk and Aspirin.
The various areas that Heikki Järvinen examines in his Gastroenterology study include Pouch, Colectomy, Ulcerative colitis and Prospective cohort study.
His Germline mutation research incorporates elements of Cancer research and MSH2.
His most cited work include:
- Clues to the pathogenesis of familial colorectal cancer (2375 citations)
- Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer (2028 citations)
- Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer (1108 citations)
What are the main themes of his work throughout his whole career to date?
Heikki Järvinen spends much of his time researching Internal medicine, Colorectal cancer, Gastroenterology, Cancer and Genetics.
The Internal medicine study combines topics in areas such as Surgery and Oncology.
He has included themes like Rectum, Cancer research, Microsatellite instability and Pathology in his Colorectal cancer study.
His work in Cancer research covers topics such as Carcinogenesis which are related to areas like Somatic cell.
His biological study spans a wide range of topics, including Survival rate, Colectomy, Proctocolectomy, Carcinoma and Risk factor.
His primary area of study in Cancer is in the field of Endometrial cancer.
He most often published in these fields:
- Internal medicine (48.64%)
- Colorectal cancer (44.56%)
- Gastroenterology (24.49%)
What were the highlights of his more recent work (between 2012-2021)?
- Colorectal cancer (44.56%)
- Genetics (22.79%)
- Lynch syndrome (13.27%)
In recent papers he was focusing on the following fields of study:
Heikki Järvinen mainly investigates Colorectal cancer, Genetics, Lynch syndrome, Internal medicine and Exome sequencing.
To a larger extent, Heikki Järvinen studies Cancer with the aim of understanding Colorectal cancer.
His work in Cancer addresses issues such as Mutation, which are connected to fields such as Epidemiology and Pediatrics.
Heikki Järvinen combines subjects such as Cancer research, Carcinogenesis, Colonoscopy, Endometrial cancer and Genetic testing with his study of Lynch syndrome.
His Internal medicine course of study focuses on Oncology and Mendelian inheritance.
As part of one scientific family, Heikki Järvinen deals mainly with the area of Exome sequencing, narrowing it down to issues related to the MLH1, and often Familial Colorectal Cancer Type X.
Between 2012 and 2021, his most popular works were:
- Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts (483 citations)
- CTCF/cohesin-binding sites are frequently mutated in cancer (276 citations)
- Stochastic Parameterization: Towards a new view of Weather and Climate Models (168 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
Heikki Järvinen focuses on Colorectal cancer, Lynch syndrome, Genetics, Internal medicine and Mutation.
His Colorectal cancer research is classified as research in Cancer.
His Lynch syndrome research incorporates themes from Colonoscopy, Gynecology, Incidence and Endometrial cancer.
His Internal medicine research integrates issues from Rehabilitation, Physical therapy and Oncology.
His MSH6 study in the realm of Mutation connects with subjects such as Splice site mutation.
His study in Exome sequencing is interdisciplinary in nature, drawing from both Familial Colorectal Cancer Type X, MLH1, DNA mismatch repair and Germline mutation.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
